CFD’er er komplekse instrumenter, og der er en stor risiko forbundet med disse for at miste penge på grund af gearing. 77.3 % af detailinvestorerne har tab på deres konto, når de handler CFD’er med denne udbyder. Du skal overveje, om du forstår, hvordan CFD’er fungerer, og om du har råd til at løbe en stor risiko for at miste dine penge.

Close

Handel Vir Biotechnology VIR

Sælge
 Køb

VirBiotechnology live diagram

5m 15m 30m 1h 4h 1d 1w

Grundlæggende Instrumenter

Weekly Search
Weekly
Daily
Dato Luk Ændring % Ændre Åbn Høj Lav

Seneste nyheder

Frances Wang 2025 Apr 24, 16:00

How will tariffs affect forex: EUR/USD pair weakens amid trade uncertainty

Forex
Frances Wang 2025 Apr 24, 16:00

Exchange Traded Funds News: Tech-Focused ETFs Gain Traction Amid AI Boom

ETFs
Tommy Yap 2025 Apr 24, 16:00

Morning Note: US-China Trade Deadlock; Nvidia's AI Leap; Canada Votes

Morning Note CAD Forex
Frances Wang 2025 Apr 24, 16:00

Popular CFD trading platforms 2025: eToro, Plus500, IG, MT4, MT5 and more

CFD Trading
Frances Wang 2025 Apr 23, 16:00

Hang Seng Index Gains on Strong China GDP amid Trump Tariffs Uncertainty

Indices
Frances Wang 2025 Apr 23, 16:00

Forex news today: GBP/USD gains, USD/JPY declines, EUR/USD strengthens

Forex
Frances Wang 2025 Apr 23, 16:00

Trending stocks to watch: AMD, GOOG, NVDA, AMZN, MSFT

Stocks
Tommy Yap 2025 Apr 23, 16:00

Morning Note: Tariff Deadlock Grips US-China Trade; Alphabet's Report Looms; BOJ Dilemma

Morning Note Tech

Info

Spread

0.07

Spread (%)

1.1218 %

Gearing

1:5

Dag til dag-rente Køb

-0.0597 %

Dag til dag-rente Sælg

-0.0292 %

Valuta

USD

Åbningstider for handel

Market lukket

Fredag

13:31 - 19:59

Mandag

13:31-19:59

Tirsdag

13:31-19:59

Onsdag

13:31-19:59

Torsdag

13:31-19:59

Analyse og statistikker

Åbn

---

Forrige luk

---

52 uger høj/lav

--- – ---

Markedsværdi

824242048

Aktier udestående

138064000

Indtjeningsdato (Næste)

0000-00-00

Udbytteprocent

Ex-udbyttedato

Forventet årlig udbyttesats

0

Forventet årlig udbytteprocent

0

EPS

-3.94

Få mere at vide om dette instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Relaterede instrumenter

Aktiv
Sælge
Køb
% Ændre

Handl nu

Handl nu

Handl nu

Handl nu
Relaterede instrumenter
Trustpilot